Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-02-14, Stock:NVS, The news for the past five days is as follows:
2019-02-07: NEWS1: Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19.NEWS2: Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19.NEWS3: Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19.NEWS4: Novartis CEO lauds Trump administration plan to overhaul rebates.NEWS5: Novartis CEO says U.S. rebate plan will return cash to patients.
2019-02-08: NEWS1: Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?.NEWS2: Incyte Down as FDA Extends Review Period of Jakafi for GVHD.NEWS3: Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View.NEWS4: Ligand Pharmaceuticals Inc (LGND) Q4 2018 Earnings Conference Call Transcript.
2019-02-11: NEWS1: Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?.NEWS2: Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?.NEWS3: Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?.NEWS4: The roots of “servant leadership” management culture date back to Hermann Hesse and a young Hillary Clinton.NEWS5: Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View.NEWS6: Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View.NEWS7: Incyte Down as FDA Extends Review Period of Jakafi for GVHD.NEWS8: Incyte Down as FDA Extends Review Period of Jakafi for GVHD.NEWS9: Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?.NEWS10: Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?.NEWS11: [$$] Big Pharma’s Big Cancer Hope Is Fizzling.
2019-02-12: NEWS1: Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100.
2019-02-13: NEWS1: Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report.NEWS2: Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report.NEWS3: Conatus (CNAT) Completes Enrollment in Phase II NASH Study.NEWS4: Conatus (CNAT) Completes Enrollment in Phase II NASH Study.NEWS5: Top Research Reports for ExxonMobil, Merck & Danaher.NEWS6: Top Research Reports for ExxonMobil, Merck & Danaher.NEWS7: Conatus (CNAT) Completes Enrollment in Phase II NASH Study.NEWS8: Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report.NEWS9: Clinigen agrees to buy U.S. rights to Novartis' cancer drug Proleukin.NEWS10: Top Research Reports for ExxonMobil, Merck & Danaher.NEWS11: Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100.NEWS12: Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100.

Answer: Rise